TP53 and acute myeloid leukemia: The influence of SFRP2’s downstream effector molecules, especially TP53, which is frequently dysfunctional in elderly AML, deserve further investigation since overexpression of SFRP2 in TP53-deficient osteoblasts is linked with osteosarcoma development [29].